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This study sought to examine the cost drivers of health care and cost containment 
measures in employer sponsored medical scheme. A retrospective case study was 
carried out. The study included the entire population of the scheme beneficiaries. Both 
quantitative data and document review were used. Quantitative data was expenditure 
in Kenya shillings, secondary data collected from the Electronic Medical Record 
(EMR) from 2011 to 2015. Document review of policy document and operation 
manual of the medical scheme was done to establish cost containment measures put in 
place by the medical scheme in study. 
A descriptive analysis was done on the data. The finding were, chronic conditions, 
pharmaceutical, medical technology, administration expenditure, length of hospital 
stay, doctors consultation had an upward trend. Doctors’ consultation expenditure was 
the highest in the five years. Chronic conditions had higher share than pharmaceutical 
expenditure. Higher escalation of cost was demonstrated in all the variables in 
2013.This study contribute to the understanding of expenditure growth trends in an 
employer sponsored medical scheme. The study found that utilization policies and use 
of guideline play a big role to a scheme expenditure output. From the literature review, 
Cost containment measures have been used in different countries and have yield 
positive results. These measures range from government policies to incentives for both 
health care givers to patients. The study recommends policy reform and utilization of 
committees to contain cost. 
There is need to explore cost drivers individually in detail especially doctors’ 
consultation, chronic conditions, pharmaceutical, administrative and medical 
technology expenditure in different employer sponsored medical schemes. 
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CHAPTER 1: INTRODUCTION 
1.1 Background of the Study 
Health care has tremendously evolved since the 19th century. Studies have shown that, 
globally the evolvement has come with increased health care costs due to advancement 
in technology, new diagnostic approaches, and innovation in therapeutic and surgical 
interventions as well as demographic changes. The growth of health care spending and 
GDP of a country correlates, this according to Fuchs, (2013). He continues to state that 
from 1950 health care expenditure grew at a rate of 4.4% and continued to increase to 
17.9% in 2011. Health care spending has been increasing and expected to continue 
rising in both developed and developing countries (Porter, 2013). 
According to the WHO (2014), a country’s health expenditure goes high as its gross 
domestic product (GDP) rises. Erixon & Van der Marel, (2011) acknowledged that 
there was no available data to conduct quantitative research to quantify this 
phenomenon. From Organization for Economic Cooperation and Development 
(OECD) health data, health expenditure has been growing higher than the annual mean 
growth rate of per-capita GDP in most countries except Ireland and Sweden. This is 
different in Portugal, Spain and Greece where health care expenditure growth rate has 
been higher compared to other countries while their GDP is mean(Erixon & Van der 
Marel, 2011).  
Wealthy countries globally, have struggled with cost escalation and control in their 
health systems. Since 1970, per-capita expenditure on healthcare has been growing 
approximately 4% in real terms. Norway at approximately 5.5%, Japan and Spain at 
4.9%, and Ireland at 4.5% while Netherland and Canada have grown at a rate of 2.5% 
(Erixon & Van der Marel, 2011) . With time some countries have actually managed to 
control health expenditure growth rates, meaning that it is practical to arrest healthcare 
costs with the right policies. For example, Greece registered negative growth rate; i.e. 
from 5.4% (2005-2009) to -7.2% (2009-2013) and Ireland from 5.3% (2005-2009) to 
-4% (2009-2013) (OECD, 2015). 
The reduction in health care costs for Greece and Ireland was due to reduced spending 
on pharmaceutical, preventive care and improved on primary health care.  Cost cutting 
measures included, policies that changed entitlement, benefits and user charges as well 
as structural reforms. Other measures in the pharmaceuticals was delisting of drugs 
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and imposing cuts on ex-factory prices on patent and or generic drugs. In particular 
Greece cut the prices paid and promoted the use of generic drugs and reduced 
outpatient care spending.  While Ireland introduced incentives and information to 
patients on generic drug including incentives to pharmaceutical and doctors dispensing  
and prescribing generics respectively (OECD, 2015). 
WHO (2014), the period 2005 to 2014, generally Sub Saharan Africa countries have 
had a steady growth in total health expenditure as percentage of the GDP, slightly 
above the trend exhibited by Europe and Central Asia and way above Middle East and 
North Africa. For instance, South Africa spent about 8.8% of its GDP on health in 
2012 up from 8.4% in 2009, slightly below the OECD mean of 9.3%, Swaziland spend 
9.3% in 2014 up from 8.5% in 2009 and  Guinea, 5.6% in 2014 up from 3.8% in 2009.  
In Kenya, health expenditure growth rates have been equally rapid. Total health 
expenditure (THE) increased from Kshs 82.2 billion in 2001/02 to Kshs 122.9 billion 
in 2009/10,  (MOH, 2011). Translating to 5% of the GDP in 200/02 and 4% of the 
GDP in 2009/10, (WHO, 2014). THE per capita increased by 49%, from Kshs 2,636 
in 2001/02 to Kshs 3,203 in 2009/10. In 2014, THE of the GDP was at 5.7% (WHO, 
2017). Expenditure on Pharmaceuticals has majorly contributed to the increase in 
health care spending in Kenya. For example in 2016 Kenya spend Kshs 83.84billion  
up from Kshs 73.35 billion in 2015, representing 14.3%annual growth rate (World 
Bank, 2016). There is no evidence that specific measures have been taken to control 
cost escalation in the Kenyan health sector. 
1.1.1 Brief History of in House (employer-based) Medical Scheme 
Following the World War I, Workers could not pay for their medical care due to the 
hyperinflation. As a result administration instituted control in wages and price that led 
to many labour groups to react resulting to strikes. In concession to the labour groups 
and to end the strike, the War Labour Board exempted the employer who extended 
health benefits to their employee from income tax. The tax advantage was the 
employers’ incentive to put in place health insurance plans for their employees. As a 
result the employers received a 100% tax deduction while the employees were exempt 
from federal, state, and city taxation. In 1940, the employer sponsored health care 
model was started (Lindquist, 2014). 
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In a different scenario, industries with high occupational injury rates employed 
company doctors and nurses to treat workers. A good example was Kaiser Permanente 
which grew out of employer-sponsored clinics to provide care for workers in shipyards 
and steel mills before World War II (Royse, 2015). 
According to (Doherty & McLeod, 2002), medical schemes have evolved over time 
because of escalating health care costs. As a result the government (South Africa, made 
it compulsory for schemes to have packages of both hospital and outpatient services. 
This package was referred to as Prescribed Minimum Benefits (PMBs) and viewed to 
be superior services to those offered in public hospitals. However the beneficiaries to 
this scheme contribute on basis of salary and number of dependants.  
An escalation in the cost of health is not only felt by governments but also by 
households, employers and insurance firms. 
No available data on employer- sponsored medical schemes in Kenya. This study is 
about employer-sponsored medical cover with a focus on an organization in Kenya. 
This organization has in-house Clinics in major towns in the country. The beneficiaries 
to the medical scheme have been growing over time as the policy allows. The scheme 
too has escalating health care spending that is of concern to the management. 
1.2 Problem Statement 
The medical scheme in study covers staff members and their dependants. The period 
between 2010 and 2015 has seen a significant growth in the number of beneficiaries 
at mean rate of 6% per annum. 2015 registered 4786 scheme beneficiaries from 3572 
members in 2010.  This growth has been accompanied by a decrease in expenditure 
from 145m in 2011 to 139 in 2013 and a significant escalation in cost to Kshs. 182m 
in 2014 and 183 million in 2015, Medical scheme analysis(2010-2015).  The 2014 
expenditure growth rate represented a whopping 30.9% increase over that of 2013, 
Electronic Medical Record (2017). This scenario translates to a per capita expenditure 
range of Kshs. 29,024 in 2011 to 36,211 in 2015 which invariably is way above the 
national per capita of Kshs. 3,203, a situation that has increasingly been of  great 
concern to management. 
Literature suggests that some of the health care cost drivers include demographic 
changes, pharmaceuticals, administrative cost, inflation cost, chronic diseases, 
uncoordinated care and long hospital stay, price inflation, medical fraud, long term 
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care and physicians’ consultation.  As demonstrated by studies by (Erixon & Van der 
Marel, 2011) and  Fuchs, (2011) among others. So this study intends to investigate the 
key cost drivers for this study case from 2011 to 2015 and the measures in place to 
contain cost. As it is currently like any other payer of health care, there is concern with 
the rising health spending in the medical scheme in study.  To ensure sustainability of 
the medical scheme to her staff, it is critical to intervene and contain the rising cost of 
health care in the beneficiary scheme. 
If this trend of escalating cost is not contained it will lead to the employer experiencing 
added cost and eventually result to measures like closure of the clinics. Subsequently, 
this would lead to loss of workforce, low productivity, loss of man hour because staff 
would go to seek for health services within working hours, increased absenteeism. 
(Quelch, 2016), medical scheme is important because the medical services lowers 
overall healthcare costs through screening and early detection of chronic diseases, less 
absenteeism, employee retention, fewer workplace injuries, stronger growth, enhanced 
corporate reputation, productivity and reduced mortality rate. Because “The more 
robust your company’s ‘culture of health.’ And, importantly, companies with robustly 
healthful cultures reap other, more quantifiable benefits” (Fortune, 2016 pg. 1).  
At institutional level, a thorough exploration of the key cost drivers of the medical 
scheme is undertaken. The findings of this study will be useful to management of other 
employee medical scheme by providing appropriate suggestions on optimal strategies 
for medical care cost containment. There is no available data on employer- sponsored 
medical schemes in Kenya. 
1.3 Research Objectives 
1.3.1 Overall objective 
To examine the cost drivers of health care for study case employer medical scheme. 
1.3.2 Specific Objectives 
1. To critically analyze the cost drivers for healthcare in the study case employer 
medical scheme. 




1.4 Significance of the Study 
Employer-medical scheme benefits both the employer and the employee and by 
extension the staff dependants and therefore containing health care cost is an important 
effort. This study contributes to the understanding of expenditure growth trends in an 
employer sponsored medical scheme and the role of utilizing policies and guidelines 
to control the expenditure of the scheme. 
These research findings will assist the management of employer sponsored medical 
scheme to make informed decisions and contain the medical expenditure. This study 
will also inform the organization’s medical team, as gatekeepers of health care 






CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
Literature review is evaluating information from the literature that is related to study 
area,(Libbie Blanchard,2017)This section reviews empirical literature on health care 
cost drivers and strategies to control costs.  Literature review was conducted through 
review of the published and grey literature from the internet 
2.2 Causes of Cost Escalation in the Health Sector 
This section presents review of the global cost drivers and appreciates how they 
contribute to cost escalation. In this section the researcher has focused on reviewing 
the common cost drivers that other scholars discovered. 
2.2.1 Pharmaceutical Expenditure 
Many studies have attributed pharmaceutical expenditure growth with economic 
growth, new drugs and aging population. Pharmaceutical spending has been a major 
cost driver for health care, it takes up to a fifth of total health expenditure that is; for 
every one dollar on health is spend on pharmaceutical OECD, (2015). To demonstrate 
this, in 2009 the pharmaceutical spending in OECD was more than USD 700 billion 
equivalent of 19% total health spending OECD, (2011). While in 2013 the 
pharmaceutical spending was USD 800 billion equal to 20% of the total health 
spending in OECD countries  Indicators,( 2011).  Pharmaceutical spending in  United 
States was highest per capita, USD 947 in 2009, double the OECD mean of USD 487 
(OECD, 2011). 
 Pharmaceutical spending as a percentage of the total health expenditure: 
Table 2.2.1 Pharmaceutical Spending 
  2009 2010 2011 2012 2013 2014 
Hungary 32.9 33.3 35 32.6 30.3 30.2 
Greece 29.7 30.4 34.8 29.4 29.3 28.4 
Canada 17.8 18.4 18.2 17.8 17.4 17.2 
Germany 15.3 15 14.3 14.2 14.1 14.5 
Ireland 15.1 14.8 14.4 14.1 14.5 14.1 






Profit seeking behavior of health care service providers, waste, and inefficiencies are 
cause of increased health care resulting to reduced access and increased medical 
impoverishment. For instant, China prescribes antibiotics to 75% of common cold 
cases way above the international mean of 30%. China’s health care spending has been 
growing at a rate of 16% per annum cited from Zhou, 2008 (Yip & Hsiao, 2008). 
Sub- Saharan Africa relies a lot in importing pharmaceuticals. With increase in non-
communicable diseases and increase in health care costs has led to the increase trend 
of manufacturing medicines (BMI, 2015). Developing countries often manufacture 
analgesics and import medicines like for Tuberculosis making them very expensive 
(Mysorekar, 2013) 
In Kenya, there are 45 licensed pharmaceutical manufactures with a market share of 
28% was registered in 2010. The total pharmaceutical expenditure (TPE) in 2006 was 
26,796 million, accounting for 36.64% of the total health expenditure (MOH, 2010) 
compared to TPE in 2010 that was.  
2.2.2 Demographic Shift 
Aging was a trend for the developed countries but this has changed now to a global 
phenomenon. In developed countries, the share of those aged 60 years and above was 
22% of the population in 2012 up from 12% in 1950 and is expected to rise to 32% 
(418 million) by 2050. While developing countries the share of those 60 years and 
above was 9% in 2012 up from 6% in 1950 and is expected to reach 20% (1.6 billion) 
by 2050.  (Beard et al., 2012) 
Health care spending grows everywhere because of aging of the population. Age 
distribution of U.S has added 0.2% to the rate of health care expenditure growth rate. 
Those  who were born between 1945 and 1964 (  Baby boomers) will increase the 
effect (Fuchs, 2011b). 
(Canizares et al. 2016) and (Neuman, Cubanski, & Damico, 2015),  health care 
spending increases with age. Above 80 years individuals are likely to have chronic 
illnesses and hence several the specialist care, inpatient or emergency department thus 
increase in health care spending which compared baby boomers and other generations 
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on utilization of health care services, older individuals utilized health services more 
than younger ones.  
In low income and middle income countries have overall increase in health care 
spending because of increasing population and higher proportion of the elderly(Gottret 
& Schieber, 2006). Kenya  population is estimated to be 46 million, growing at an 
mean of 1 million per year with a median age of 19years (Kenya Healthcare Federation 
( & Task Force Health Care, 2016). Gottret & Schieber argue that in Sub-Saharan 
Africa which is characterized with high population growth rate increase their health 
care spending by 52% overall, of this 43% is as a result of population growth and 9% 
as a result of age sex structure changes. in Europe and Central Asia with almost no 
population growth rate and long life expectancy, increase in health spending is by 14% 
overall, of this 1% is as a result of population growth and 13% as a result of age sex 
structure changes. 
2.2.3 Medical Technology Expenditure 
Medical technology refers to procedures, equipment, and processes by which medical 
care is delivered, Goyen & Debatin, (2009). Technological change is one of the driving 
forces behind rising of health care spending (Fuchs, 2011). 
Several factors are blamed for the growth of health care spending as a result of medical 
technology. The overuse of the new technology in attempt to treat what was not 
treatable before, increase patients’ demand, substituting treatment strategy that was 
cheaper,  new knowledge on diagnosing conditions and accumulation of patients 
requiring the same particular treatment hence a growing population, (Goyen & 
Debatin, 2009) 
 In 1960 to 2000, a study by (Cutler & McClellan, 2001),  medical technology was 
found valuable if the benefits of medical advances exceeded the costs. The study 
analyzed heart attack, depression, cataract and low birth weight infants and how 
medical technology benefits outweighed costs. In these conditions, technological 
change was much greater than the cost because life expectancy increased seven-fold.  
Different findings were noted from March et al., (2008) and Sorenson, Drummond, & 
Bhuiyan Khan, (2013) that medical technology did not have a significant role in health 
care expenditure.  March et al found out that medical devices account for a relatively 
small share of national health expenditures (3%–5%). The study observed that, post-
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operative costs were lower compared to preoperative costs for total knee replacement 
or total hip replacement. Out-of-pocket costs of osteoarthritis total knee replacement 
patients decreased from $379 for the 3 months preoperatively to $306 and $128 at 3 
and 12 months postoperatively respectively. 
More is needed to understand the real expenditure per head for every medical 
technology advanced. From the literature, there is no clear cut on how much the 
medical technology contributes to the growth of the healthcare expenditure. There are 
no direct measures of health care spending regarding medical technology but rather by 
exclusion of the impact that were measurable like, increased insurance uptake, increase 
per capita income, increased life expectancy, supplier-induced demand and then the 
unexplained residue increase would be regarded as increase due to medical technology. 
2.2.4 Administrative Expenditure 
Administrative costs are made to improve the overall economic performance of a 
hospital as well as its medical care (HealthManagement.org, 2016). 
Hospitals Total Administrative Cost among six countries showed; United States, at 
25.3%,Netherland at 20%, England at 16%, Scotland at 12%, Canada 12%, Wales at 
14% of the US hospital expenditure.  Total hospital costs were highest in the nations 
that had the highest hospital administrative costs and yet there was no evidence that 
high administrative costs translated into superior care (Himmelstein et al., 2014) 
According to (NHA, 2010),Eastern and southern Africa countries, ranged differently 
in administration cost in 1997/98 among the NGOs and for profit private institutions. 
This report stated as; Kenya 2.53%, Rwanda 23.92%, Ethiopia 7.19%, Uganda 4.75%, 
Malawi 11.18%, Tanzania 11.9% and South Africa 6.11% as percentage of total 
expenditure. 
2.2.5 Chronic Diseases Expenditure 
Chronic diseases in this study include cancers, heart conditions (Ischemic heart disease 
heart failure), diabetes, hypertension, hyperlipidemia, pulmonary conditions, Arthritis, 
mental conditions (Depression, Schizophrenia, and other psychotic disorders, human 
immunodeficiency virus, acquired immunodeficiency syndrome, chronic renal 
conditions and musculoskeletal disorders (Nolte & McKee, 2008). The estimated 




By 2020 the number of Americans living with at least one chronic condition is 
estimated to be 157 million growing from 133 million in 2005.This will increase the 
cost burden of chronic illness beyond 78% of total health spending.  (Bodenheimer, 
Chen, & Bennett, 2009) . 
In Sub-Saharan Africa, HIV/AIDs, Tuberculosis and Malaria have been prevailing but 
now the trend is changing and non-communicable diseases (NCDs) are emerging as 
the current burden. These NCDs include; injuries 12%, sense organ disorder 3%, 
cardiovascular diseases 4%, neuropsychiatric disorder 7% of the global burden disease 
(Gottret & Schieber, 2006) 
According to (World Health Organization, 2014), Africa communicable diseases like 
HIV and Tuberculosis contribute to 2/3 of the total disease burden while the rest is due 
to NCDs and injuries. These NCDs including diabetes, cardiovascular disorders and 
cancers are increasing cause of death and health care costs. 
2.2.6 Uncoordinated Care and Long-Stay Expenditure 
All other things held constant mean length of hospital (ALOS) stay is an indicator; a 
shorter ALOS is less costly. In 2014, ALOS was 16.9days, 8.3days, 7.6 days, 5.1days, 
3.8days for Japan, Korea, Germany, Israel and Turkey respectively (OECD, 2017b). 
Many studies show that uncoordinated care can lead to longer hospital stay, 
complication of diseases, duplication of treatment and drugs, poor customer 
experience and hence high cost of health care services. As stated  by Girod & Weltz, 
(2015),that providing health care is like building a house and a task that requires 
experts, expensive equipment and materials, and coordination.  
According to, (Hibbard & Greene, 2013) “Bed blockers” referring to patients staying 
in hospital bed awaiting appropriate follow up care and what is perceived as shortage 
of non-acute care beds. This is scenario of failure in efficient coordinated care which 
is common in many OECD but frequent in Germany, Greece, Ireland and Korea. This 
never happens in Belgium, Hungary and Mexico. More study is required to understand 
how Bed blocking increases in health care expenditure. 
In Nigeria a study done by (Somotun, Osungbade, Akinyemi, Obembe, & Adeniji, 
2017), showed that different medical condition detected different length of Hospital 
stay. For example, in mean diabetic stayed 14.03 days compared to Ghana whom the 
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diabetic stayed for 6.2 days, ischemic stroke stayed 14.4 days (plus or minus 9.8 days) 
compared to UK and India whom ischemic stroke stayed 7days. 
2.2.7 Price Inflation 
From medical data, the medical care Consumer Price Index (CPI) increased by 1.8% 
annually above all prices of all other items CPI between 1960 and 1999 (Cutler & 
McClellan, 2001). According to (Folland, Goodman, Stano, & others, 2007) the 
possibilities of inflation in health  could be utilization of health care services resulting 
to more consultation, or more tests being ordered by the health care providers and or 
prescribing more drugs. Two, health care services may be higher in quality including 
products and services that didn’t exist before. For example, laser surgery, organ 
surgery that was not there until in 1960.  These new interventions are costly and of 
more quality, cause people to be willing to pay more for better quality. Thirdly, the 
health care inflation could be higher than the general inflation because for example in 
the U.S the income is higher for service provider and prevalence of insurance is higher. 
Increase in demand for healthcare services is cause for growth in health care cost.  
Demand alone cannot explain the large share of medical care expenditure. Inflation 
rate was found to be the substantiated findings for price growth in France, Sweden and 
the UK. Increase in general physicians was higher than the inflation rate in the three 
countries (Erixon & Van der Marel, 2011). 
2.2.8 Long Term Care Expenditure 
Long Term Care (LTC) in this study refers to the assistance a patient receives as a 
result of chronic illness or disability that leaves a patient unable to care for themselves 
in prolonged period of time (Rider, Stum, & McNamara, 2004).In this study, the 
researcher refers LTC as more than 100days in a single hospital admission or Home-
care with or without a social worker. 
LTC spending continued to grow even after 2009 exceeding pre-crisis years in nearly 
a third of OECD countries, Japan and Germany inclusive. In Portugal, long term care 
spending increased by around 7% annually. In Korea expenditure for long term care 
increased as a result of measures to expand coverage in their LTC system (OECD 
health statistics, 2015).(Werblow, Felder, & Zweifel, 2007), in the analysis of Swiss 
data, stated that health care cost was due to medical technology which is lavished on 
to patients with considerably a short time to live. 
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Contrary to many other studies that aging contribute to increasing health care costs 
(Palangkaraya & Yong, 2009), a study done in Australia stated that aged population 
may not be the main driver of health care spending. Proximity to death is a more 
important variable than aging population. Medical technology use on the terminal 
cases should be reduced by government putting a public policy on medical technology. 
Further acknowledges that such decision would be more of social choice rather than 
medical or economical because technologies have prolonged lives but leaving those 
behind with huge medical bills.  
Bedside rationing has been defined as occurring when a physician withholds services 
that are, in the physician’s best clinical judgment, in the patient’s best medical 
interests, in order to promote the financial interests of someone other than the patient. 
Bedside rationing is prevalent in European countries and varies with physician 
attitudes and resource availability. The prevalence of physician bedside rationing, 
which presents physicians with difficult moral dilemmas, highlights the importance of 
discussions regarding how to ration care in the most ethically justifiable manner 
(Lauridsen, 2009).Empirical studies on LTC is very limited and the clinical practice 
on rationing. 
2.2.9 Doctors’ Consultation Expenditure 
The health care service provider plays a big role cost reduction. They act as the 
gatekeepers in health care. According to (Lauridsen, 2009) “administrative gate 
keeping” is the alternative available for physicians to be involved in rationing of 
healthcare cost without violating their true advocacy of their patients that is not 
denying his patient quality of care. In OECD countries doctors’ consultation per year 
per capita in 2014 was; 14.9 per capita,11.8 per capita,11.3 per capita, 2.6 per 
capita,2.9 per capita,4.2 per capita in Korea, Hungary, Slovak Republic, Mexico, 
Sweden and Finland respectively (OECD, 2017). 
The physician has broader power in making decision pertaining patient care utilization 
virtue of his knowledge and authority by law. He admits and discharges patient from 
the hospital, recommends on surgery, requests for laboratory tests, radiology as well 
as prescribing drugs. All this roles add up to contributing to health care costs.(Fuchs, 
2011a) 
2.1.1.10 Medical fraud 
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Oxford dictionary define fraud as a wrongful or criminal deception intended to result 
in financial or personal gain. European countries spend more than 1 trillion Euros a 
year on healthcare services for their citizens. Yet 56 billion Euro of this budget gets 
lost to fraud annually and 180 billion Euros ($260 billion) globally. This study 
reported, range of percentage losses Rate (PLR) was found to be between 3.29% and 
10.00% with an mean PLR of 5.59 that is the proportion of expenditure lost to fraud 
and error (Gee, Button, & Brooks, 2010). 
Medical fraud range from collision between providers and pharmaceuticals sector, 
kickbacks given by pharmaceuticals to hospitals for moving their products. The 
kickbacks are extended to the prescribing doctors. Unethically, doctors buy expired 
and counterfeit drugs and sell them at a profit as valid products (Yip & Hsiao, 2008). 
Fraud and abuse accounted between 3 to 15% of the annual expenditure for health 
care. Per year the cost of fraud and abuse ranged from 100 to 170 billion with only 
recovery of less than 5%.  This can be due to  misrepresentation of services with 
incorrect Current Procedural Terminology (CPT) codes; billing for services not given; 
altering claim forms for higher payments; or false information in medical record 
documents  (Rudman, Eberhardt, Pierce, & Hart-Hester, 2009).  
2.3 Potential Strategies for Cost Containment 
“One force motivating convergence is that almost all the countries face a common 
problem –how to slow the rate of growth of health care spending” (Fuchs, 2011b) the 
researcher reviewed cost containment measures that have been used elsewhere and 
yielded results. 
2.3.1 Pharmaceutical Control Measures 
Expenditure for pharmaceuticals has been cut annually by nearly 2% after positive 
annual increases of 2% in the pre-crisis years still down on previously strong growth 
in pharmaceutical spending in the 1990s and early 2000s. Cost containment measures 
like price cuts, the introduction of references pricing, compulsory rebates, reduction 
of pharmacy margins and value added tax, the end of patents and the rise use of 
generics have all contributed to the reduction in pharmaceutical spending. (OECD 
health statistics, 2015). 
 Between 2009 and 2013, some countries had taken measures to reduce cost escalation 
from pharmaceutical expenditure. For example, pharmaceutical expenditure declined 
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by 3.2% on mean across the OECD countries. Steeper declines in pharmaceutical 
expenditure were registered in Portugal (-11.1%), Denmark (-10.4%), and Iceland (-
9.9%). The reduction of public pharmaceutical spending in OECD countries was due 
to a range of policy measures and reforms that aimed at shifting some burden of 
pharmaceutical spending to private payers. For instant, Ireland introduced a 50-cent 
prescription fee for medical card holders in 2010. Drug reimbursement threshold was 
raised by 20% in every month for non-medical card holders, increased the use of 
generic and termination of patents. Most of the OECD countries took measures that 
included pharmaceutical regulations, reduction of wages in public hospitals, delaying 
to replace staff and in developing the hospital infrastructures 
France, Germany, Sweden, and the United Kingdom each use different types of 
policies for controlling prescription drug spending. Until recent years, these policies 
have relied heavily on regulating prices charged by drug manufacturers, with different 
systems providing varying degrees of pricing freedom. While these policies appear to 
have brought some degree of price restraint, they have not prevented continued growth 
in prescription drug spending. As a result, each country is supplementing its policies 
with measures aimed at physicians and consumers and targeted at reducing a perceived 
over-utilization of pharmaceutical products.(Dj, J, J, & Sl, 1994) 
(Doherty & McLeod, 2002), use of formularies in control of cost in medical scheme 
has been used. Formularies are determined list of drugs that are clinically effective and 
cost effective. Reimbursement by the scheme is only those that are in formulary. 
However, beneficiaries can take up other products outside the list if they are willing to 
pay for the difference. In this list most schemes prefer generic as opposed to brand 
name drugs. Particularly the use of generic drugs in chronic medicine it has proven to 
be successful in reducing cost escalation in many schemes. (Purcell, 2009) states that, 
tiered co-payment by beneficiaries would be used as a measure to control cost. Tiered 
co-payment is where by beneficiary pays for the extra money outside the formulary 
mainly the for the brand drugs. This is made to encourage utilization of generic 




2.3.2 Administrative Gatekeepers 
It is argued by (Doherty & McLeod, 2002) that most mechanisms are made to 
encourage appropriate utilization of the services. As stated by (Purcell, 2009) the 
beneficiaries decisions drive most of the health care costs and therefore their decisions 
should be influenced in order to lower health care costs. In addition to influencing the 
beneficiary decisions, Purcell redirects attention to be focused on the plan of the 
scheme, arrangements on payments towards the scheme and factors that influence 
demand for services in the scheme. 
Having administrative control and planning in place as measures to contain cost. This 
can include having utilization committees, drug formularies, and wages and price 
ceilings (Fuchs, 2011a). 
Managed care, refers to use selective networks of contracted providers as means of 
encouraging beneficiaries to use the networks and share risks with these providers. 
Network of providers under this strategy are paid monthly a fixed fee to provide care 
to a group of patients. This is referred to as Capitation. Capitation caters for the 
negative incentives brought about by fee-for-service. Further, (Doherty & McLeod, 
2002) states that the provider assumes some of the scheme risks and limits overuse. 
Under capitation the provider is bound to under-supply which therefore calls for 
monitoring from the administration.  
Risk-sharing and the provision of low-cost options can be used by the administration 
to control cost. In this case, hospital risk- sharing is done through per diem (Doherty 
& McLeod, 2002). In per Diem charges are per day or per case basis and not per item. 
The quality of care from these contracted hospitals became of concern. 
(Purcell, 2009) administration being proactive by auditing eligibility of the 
beneficiaries periodically to avoid providing health care services to e.g. espouses, adult 
child. Recommends that fulltime students should be required to present documents 
from school to proof they are in school. Further, Purcell encourages the administration 
to encourage spouses to disclose other medical scheme within their disposal and give 
incentive for those who utilize the other scheme for primary use. 
Schemes can negotiate for stability multi yearly contracts to ensure the scheme gets 
competitive market pricing. Audit claims trends and find out which in more. 
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Encourage contracts of lower prices for consistent purchase of drugs and  other 
consumables from vendors (Purcell, 2009). 
The scheme beneficiaries are encouraged to utilize the network of providers with 
whom the scheme has negotiated prices with and reimbursement is only costs incurred 
through these providers. Together with networked providers a scheme can add on 
capitation in order to gain risk sharing and provision of low-cost options. The 
advantage to this arrangement is it limits unnecessary care from suppliers and making 
them choose effective treatment and prevention of ill health to beneficiaries. While 
limitation, is that the provider can under supply (Doherty & McLeod, 2002). 
Pre-authorization measure is where a beneficiary requires an authorization to a hospital 
before services by the managed care organization. This measure minimizes overuse by 
the supplier and does not deny access for health care. In addition to pre-authorization 
and case management it is important to audit the hospital bills  (Doherty & McLeod, 
2002). 
2.3.4 Need and Demand Reduction 
Reducing the need and demand of medical services by improving the health of 
individuals would lead to reducing the cost of health. Some of the ways of improving 
the health of individuals include the introduction of health promotion programs, reform 
health policies, health education that is providing information to empower individuals 
to help enhance confidence in making decision on health matters and avoid 
unnecessary and under use of the medical services, improving of individuals’ 
environment, and preventive medicines (Fuchs, 2011a) 
Audit claims trends and find out which are in more demand and which can be trimmed 
(Purcell, 2009). 
A drawback to cost reduction has been from the advocates of health promotion who 
have caused delay by not putting cost reduction as a primary goal and neglecting 
vigorous economic evaluation. Some of the mentioned companies that used health 
promotion program included Johnson and Johnson, DuPont, Tenneco, Blue shield of 
California, Travelers, Southern California Edison, the County of Ventura and Coors. 
Different health promotion program put in place in this workplace, were reported to 
bring savings  (Fries et al., 2016).  
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Besides health educating the beneficiaries on healthy living and improving their habits 
and behavior that affect their health, the employers can engage the employee with 
activities that contribute to wellness e.g. walking clubs, hiking trips etc. initiatives 
prevent employee suffer from conditions that can be controlled by lifestyle (Purcell, 
2009) 
Cost reduction can also be achieved by attracting the young, those below 40years, 
before the onset of lifestyle illnesses. It is a discriminatory design because premiums 
go higher as beneficiaries advance in age and exposed to chronic conditions. (Doherty 
& McLeod, 2002) 
Disease management programs as a cost reduction measure is achieved by better data 
collection of the beneficiaries medical condition and best practice information sharing 
by the health care providers. Disease management program involves active 
management by prevention, diagnosis and treatment of specific conditions e.g. 
diabetes, Asthma. A common disease management program is HIV/AIDS, this 
program benefits are standard and beside cost containment they are accessible by 
beneficiaries on confidential basis (Doherty & McLeod, 2002). 
2.3.5 Incentives to Health Care Provider and Patient 
The desire to control health care costs has led to considerable variation in how 
employers and health insurance providers structure formularies (how drugs are 
classified), design benefits, and provide incentives to both physicians and patients. 
Many of the tools such multitier plans for drugs with introduction of co-payment, used 
to influence pharmaceutical use since 1994, were effective in reducing drug 
expenditures for working-age enrollees with employer-provided drug coverage. For 
example adding the 3-tier with increase of $ 10 co-payment reduced the drug 
expenditure by 4%. (Joyce, Escarce, Solomon, & Goldman, 2002). 
The main challenge with using formulary is changing prescribing habits of doctors, 
(Doherty & McLeod, 2002).However, Medical scheme like Medscheme  curbed this 
by introducing formulary for both acute and chronic medicines and encouraged 
primary health care doctors to use the Medscheme price list. This was used as incentive 
and integrated in their performance based reimbursement program (PBR). 
According to (Doherty & McLeod, 2002), Doctors performance can be monitored 
from data on consultation, prescription and subsequent referrals. Recommended 
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setting up a system of provider-driven peer review, in order to review practices pattern 
of their colleagues. 
2.3.6 Policy Reforms 
There is need for policies to be changed, if not countries like Germany is expected to 
represent more than 20% of GDP in its health expenditure in 15 to 20 years from now. 
This increase may not be similar to other countries but then its worthy close examining 
why healthcare costs are increasing and how health care can improve in efficient 
utilization of resources. The policymakers are not interested in doing so. The strategy 
has been to contain health care expenditure increase so as to make healthcare 
affordable for governments. Cost-containment can only achieve marginal effects, 
especially if such policies continue along current lines by addressing new and 
additional healthcare spending rather than the bulk of total spending represented by 
delivery of healthcare services. (Erixon & Van der Marel, 2011).  
In matters of the policy, seeking second opinion reduces cost. This is done with quality 
care in mind. Second opinion explores offers and appropriate medical benefits before 
a scheme incurs cost. (Barr, 2014) 
(Cutler & McClellan, 2001) warned concerning medical policies in attempts to reduce 
spending, stating that policies that eliminate waste and increase the incremental value 
of treatment may also retard technological progress either directly or indirectly. 
Therefore there is need to balance.  
2.3.7 Innovation and Review Business Model 
Innovative adjustments to the scheme benefits plan can help reduce costs. For instance, 
Prescribed Minimal Benefits (PMBs) resulted from a study that used cost data for in-
house health care services for a mining industry. PMBs exclude expensive services, 
ineffective cost services, non-urgent and non-life threatening conditions.  PMBs 
innovative design came to address the “dumping” of beneficiaries to the public 
facilities when they exhausted their limit allocation in the scheme(Doherty & McLeod, 
2002). 
Comparing health care with other industries, like telephones, cameras, planes, cars and 
investment management, health care has not taken up the challenge of changing their 
technology, value network of companies and business model to affordability to their 
products and services. Referred to as “disruptive innovation” in health care. Changing 
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technology and business model and revising the value network is all health care 
requires. Disruptive innovation has been applied at Quad/Graphics, a Wisconsin-based 
printing company in-house medical clinic and proved to work. This company set up a 
clinic in 1990 for their employee and dependants for the primary health care and 
contracted hospitals and physicians for more specialized care. The company has 
managed to spend an annual mean of $6,500 in a region where other firms are spending 
mean of $9,000 annually. This was achieved by health care regulators reorganizing 
reimbursement practices and favoring discounted prices with valued services, taking 
up the lowest price for the hospitals and physicians, encouraging disruptive innovation 
to achieve economy and accessibility. While employer provided incentives for 
behaviors that were conducive to health (Christensen, Grossman, & Hwang, 2009). 
2.3.8 Care Coordination and Patient Focused 
Countries like Finland, Germany, Spain and Sweden share electronic information for 
diagnosis and treatment between physicians and other health providers. These 
countries their care coordination is by use of disease management programs or case 
management program for patient with complex conditions requiring prolonged care.  
These diseases include coronary heart disease, breast cancer, diabetes type 1 and 2, 
asthma and obstructive pulmonary disease. Other countries like Australia, Denmark, 
France and the United Kingdom use clinical guidelines or practice protocol. Physicians 
get financial incentives to comply with guidelines. Australia physicians comply 
without financial incentives. According to OECD 2008, as cited by (Wei et al,2010), 
the government use a variety of tools that range from benchmarking, therapeutic 
referencing, pharmaco-economic evaluation and difference types of risk sharing 
agreement (Wei, Paris, & Devaux, 2010) . 
A measure suggested to American health care by (Roberts, 2014) and tested at state 
level, the U.K and Germany health care system, was use of Accountable Care 
Organization (ACO). It is an integrated patient care model that is composed of 
physicians, hospitals and other health care service providers that come together to 
share the responsibility of giving quality health care at reduced cost. In this model pay 
is for performance as opposed to fee for service model. ACO addresses the problem of 
fragmented health care services where patients see the primary care physician, 
specialist and tests done in different locations. In ACO all are done at one location 
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minimizing repetition of tests and promoting coordinated patient care. ACO focuses 
on prevention and changes mode of payment from fee –for service by creating saving 
incentives of bonuses when providers keep costs down and meet specific quality 
benchmarks. A similar highly coordinated system like ACO is Mayo Clinics (Roberts, 
2014). 
According to Roberts (2014), Mayo Clinics collects revenues from the hospitals and 
doctors and then pays salary to their doctors and other health workers, refocusing their 
workers to their goal “needs of the patient come first”. Physicians at Mayo Clinics do 
not do unnecessary procedures to their patients as their counterparts who are paid fee-
for service. Other successful and similar systems as Mayo Clinics include Geisinger 
Health System in Danville, PA; Marshfield Clinic, in Marshfield, WI; International 
Healthcare, in Salt Lake City; and Kaiser Permanente in CA. 
According to (Michiels et al., 2007), the perception of the terminally ill patient on the 
role of the General practitioner in providing continuity of care is key. Good 
coordination and effective communication from the health care providers promotes 
home care. The study emphasized on informational and relational continuity. Sharing 
of holistic information is as important as giving medication to the terminally ill patient. 
(Doherty & McLeod, 2002) argue that case management, which is active monitoring 
of patients once in the hospital to ensure beneficiaries receive clinically appropriate 
care at the right setting per the Medical Scheme. (Purcell, 2009), on managed care, 
states that  it provides case management for long term care by coordinating care and 
improving continuity and quality of care which lowers cost. For instance, cancer 
patients can be provided with homecare and social worker instead of hospital 
administration. 
2.3.9 Patient Information/ Active 
Patient engagement is an important strategy for health care reforms. Highly engaged 
patients had lower rates of costly use such as hospitalizations and emergency 
department visits, compared to less engaged patients (Hibbard & Greene, 2013). 
Patient representation and involvement in decision making is common practice among 
the OECD countries. For instant, Czech Republic, Denmark, Sweden Patients are 
represented in decision making pertaining licensing of pharmaceuticals. Australia, 
Canada, Czech Republic, Denmark, Korea, Netherlands, Switzerland, patients are 
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involved in decisions on coverage of health (Wei et al., 2010). Denmark, Iceland, 
Norway and United Kingdom involve patient representatives on hospital planning. In 
making decision on matters of public health the patient representatives are involved in 
Hungary, France, Denmark, Mexico, Iceland, Norway, Portugal, Turkey and United 
Kingdom (Wei et al., 2010). 
The role of communication in health care cost reduction cannot be overemphasized. 
Beneficiaries should be briefed at least yearly about the schemes benefit plan, the 
scheme limitations, changes, employee and employer costs and the value to employee 
(Purcell, 2009). 
2.3.10 Monetary Limits, Levies, Co-payments and Savings Accounts 
(Christensen et al., 2009), encourage the regulators of health care to reorganize 
reimbursement practices and favor discounted prices with valued services, take up the 
lowest pricing for the hospitals and physicians, encourage disruptive innovation to 
achieve economy and accessibility and employers to provide incentives for behaviors 
that are conducive to health. 
Scheme funding arrangement of a scheme is worth focusing with intention of 
containing costs. (Purcell, 2009) shares the strategy of “cost shifting”, a co-payment 
by beneficiaries in order to reduce cost from the employer. In other scenarios the 
employers have Health reimbursement arrangements. According to Purcell, the 
employer makes the contribution instead of the employee. This strategy influences the 
beneficiaries to change behavior in the utilization of the scheme. 
According to (Doherty & McLeod, 2002) and(Barr, 2014) both encourage co-payment 
by the scheme beneficiaries. They argue that it is incentive to control utilization by the 
beneficiaries. Doherty and McLeod and Purcell, (2009), further states that Monetary 
limits and savings account are strategies that have been used. Monetary limits are 
annual limits of amount of money that a scheme can reimburse in a year according to 
categories stated in the medical scheme. While saving account is when a beneficiary 
contributes monies which part of it is held in a personalized account and they can make 
decision on when to use this account towards paying for their health care. According 
to (Doherty & McLeod, 2002), Monetary limits allows only legitimate beneficiaries to 
use the medical scheme. While also it is has the disadvantage of possible denial of 
access for health care to low income groups. This was countered with introduction of 
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Prescribed Minimal Benefits (PMBs) by Medical schemes. Purcell, (2009) points out 
that Health Saving Accounts (HSAs) are tax advantaged. HSA also benefits the low 
risk beneficiaries because they do not need to cross subsidize for the non-hospital care 
for the members who are very sick. Unfortunately HSAs design has no shown to 
address cost control and not an incentive against over supply created by fee-for-
service. It targets higher income earners who are able to pay out-of-pocket the account 
is used up (Doherty & McLeod, 2002).  
Levies on the other hand are fixed amounts reimbursed per claim and different from 
co-payment in that in co-payment reimbursement is a proportion of the claim. Like 
monetary limit, it is bias to the low income. Whichever method a medical scheme 
chooses, Purcell, (2009) recommends frequent review preferably biannually. This 
allows to for example factoring in changes around demographic. 
2.4Empirical review 
Somewhat close study to this one is by (Barros, 2010). In this study Barros compared 
health care determinants of health care cost growth and containment in different 24 
countries. The findings were that aging population was significant to growth of health 
care expenditure, while the type of organizational framework (fee-for-service, 
capitation etc. ) and existence of gate keeping procedures are non-significant to 
containing health expenditure growth but rather have implication to levels of health 
expenditure other than the growth rate. This study found out that the higher a country’s 
per capita of the GDP the higher was the health expenditure. New drugs and medical 
technology was not excluded as a cost driver in these countries but encouraged more 
studies in future with better data would explain different on medical technology. 
Barros study contradicted with OECD and Gerdthan et al on earlier studies on 
organizational framework. OECD found that public reimbursement system was more 
expensive while Gerdthan et al found it less expensive. Regardless of the findings the 




 In this section literature review was done. Several common global cost drivers in 
health care and cost containment measures were identified form different scholars. 
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Among the common healthcare cost drivers identified include pharmaceutical, 
demographic shift, medical technology, administrative, chronic diseases, long hospital 
stay, long term care, doctors’ consultation expenditures and price inflation. The highest 
health care expenditure are pharmaceutical, old age and chronic diseases. 
Pharmaceutical expenditure is blamed highest than any other health expenditure. Old 
age is associated with high health expenditure because older population is argued to 
be likely to have chronic illnesses which require specialized care and more 
emergencies hence high expenditure. While chronic diseases like NCDs increase cost 
burden because of the prolonged care. Because of retirement age in employment this 
may not be a cost driver in employer sponsored medical scheme. Chronic conditions 
are neither due to old age in employer sponsored medical scheme. What are the cost 
drivers in an employer sponsored medical scheme? 
Several containment measures have been used globally. They range from 
pharmaceutical controls, administrative gate keeping, reduction of need and demand 
of services, use of incentive to health care providers and clients, policy reforms, 
innovation of business models, coordinated patient care, empowering of clients with 
information and scheme funding arrangements. 
Considering that an organization has control on utilization of the medical scheme, how 
are the expenditure trends in employer sponsored medical scheme? This study finds 
the cost drivers and how do they contribute to raising health expenditure in employer 
sponsored medical scheme. The study further reviews the employer sponsored 

































CHAPTER 3: RESEARCH METHODOLOGY 
3.1 Research Design 
The research design was a retrospective case study. A case study has been defined as 
an empirical inquiry that investigates a contemporary phenomenon within its real life 
context. According to (NEDARC, 2016), in retrospective study the researcher uses 
database available because the outcome of interest has occurred at the time of the 
study.  The researcher assessed the organization medical scheme expenditure for the 
period between 2011 and 2015. 
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3.2 Population and Sampling 
The unit of analysis of this study was the medical scheme, which constituted the 
population. This included the scheme and its in-house clinics. Data was collected from 
the EMR, of the medical scheme for 6518beneficiaries between 2011 and 2015.  
3.3 Data Collection Tools 
Data on the costs of the medical scheme and its drivers was collected retrospectively 
from the EMR as secondary data.  The data was collected for the period 2011 to 2015. 
This is because the EMR was introduced in 2010 and hence more reliable to use data 
from 2011. The EMR gave extensive information on (Appendix 1)  demographic data,  
length of hospital stay, physician’s visits and consultations, chronic diseases, medical 
Technology expenditure (MRI,CT scans), pharmaceutical expenditure, administrative 
expenditure and  long term care.   
Data on cost containment measures was collected through a review of policy 
document; policy No.72.0 Medical Scheme and the Medical Scheme operation 
manual. (Appendix 2), was used to guide in the documents review. 
3.4 Conceptual Framework 
Figure 3.4.1 shows the conceptual framework that was developed after a 
comprehensive review of literature. The conceptual framework assumes that the costs 
of a medical scheme (box D) are driven by a range of cost drivers (box A). However, 
the relationship between the cost drivers and medical scheme costs is influenced by 
the absence or presence of cost-containment measures (box B and C). The conceptual 
framework is linked to the study objective given that it shows the relationship between 
cost drivers (objective 1) and cost containment measures (objective 2). The cost drivers 
in health care are indicated. The cost drivers align with the first objective of the study 
which is to examine the cost drivers. The containment measures are the external and 
internal measures taken that affect the functional output of a medical scheme, either 
by increasing or reducing scheme expenditure. External measures are the government 
interventions while the internal are the measures put in place by the institution hosting 
a medical scheme. 
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3.5 Data Analysis 
Descriptive statistical techniques (summary statistics, tables and diagrams) were used 
to analyze the collected data. A regression model was not fitted because the study had 
a sample size of 1 (1 employee scheme) and data was collected annually. 
The researcher reviewed the medical scheme operation manual and the scheme policy 
document. The aim of reviewing these documents was to examine content on cost 
containment measures employed in medical scheme, if they are employed and identify 
gaps on cost containment. Document review is collecting data from existing 
documents, (CDC, 2009). 
3.6 Research Quality 
Given that this was a case study with a sample of 1 and a purposive sampling approach, 
it did not aim for statistical generalizability. Statistical validity and reliability therefore 
does not apply for such studies. Rather, study quality is assured by using measures that 
enhance the trustworthiness and rigor of the study.  
Figure 3.4.1 Conceptual Framework 
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A number of strategies were employed to ensure research quality. First was the use of 
theory. This study developed a conceptual framework based on a comprehensive 
review of literature. The conceptual framework guided the development of research 
tools, data collection, and data analysis. A second strategy that was employed was 
methodological triangulation. This study collected data using two strategies to 
triangulate the findings. These strategies are EMR record and review of medical 
scheme policy and operation manual. A third strategy that was employed to ensure the 
content validity of the data collection tools was to involve an expert who reviewed and 
gave his input on the validity of the tools. 
3.7 Limitations of the Study 
This study has without doubt significantly contributed findings on cost drivers and 
containment strategies for employer insurance medical schemes. However, much has 
remained to be done in future because this study was not without limitation. The 
present study has nevertheless yield usable findings.  
It was recognized that there were other cost drivers that would significantly contribute 
to the growth of the health care cost. However, the scope of this study addressed those 
which in the opinion of the researcher were relevant in the context of the organization 
being studied. For example the proposed methodology was not able measure some of 
the drivers such as medical fraud, increased demand and price inflation among others. 
3.8 Ethical Issues 
Due to confidentiality concern, the name of the medical scheme was anonymzed. The 
researcher sought for ethical clearance from IRB United States International 
University- Africa and ensured that the information accessed and the findings of the 
research study were kept confidential and was only used for academics award. 
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CHAPTER 4: RESEARCH FINDINGS 
4.1 Introduction 
The current chapter presents the findings, interpretation and discussion. Data analysis 
was carried out according to study objectives from which patterns were examined, 
interpretations done, conclusions drawn and discussion. The main objective of the 
study was to examine the cost drivers of health care for study case medical scheme. 
An initial examination revealed that, long term care expenditure was only incurred in 
one year, in the five year under examination. To achieve the first objective, to analyse 
the cost drivers of the study case, descriptive and inferential analysis were used to 
analyse the data which was presented in figures and tables. The second objective of 
exploring cost containment measures, document review was done on the policy and 
operation manual of the medical scheme.  
4.2 Descriptive Analysis 
In the study demographic shift, pharmaceutical cost, medical technology, chronic 
diseases cost, inpatient cost, chronic condition expenditure, doctors’ consultation were 
hypothesized to be the greatest contributors of medical cost. Summary statistics of the 
annual costs of each of the cost drivers are presented in table 4.2.1. Further results on 
the trends and contribution of each of the cost drivers are presented in individual sub-
sections thereafter.  
Table 4.2.1 Descriptive Analysis of the Medical Scheme 




growth rate 5 5 7 6 1 
Pharmaceutical 
Cost 5 19,278,557.82 60,223,901.34 33,544,319.08 15,701,410.79 
Medical 
Technology 
cost 5 3,791,659.50 17,443,061.00 9,962,668.07 5,148,226.32 
Chronic 




hospital stay in 
days 5 4 9 6 2 





9 83,480,724.24 33,011,328.38 
Administrative 
expenditure 5 42126862.2 76024164.7 56977000.0 13369800.0 
Long term care 
expenditure 5 0 78,800 15,760 35,240 
Doctors 
consultation 5 5,414,726.15 154,367,946.40 91,420,858.28 59,168,820.98 
Total Medical 
expenditure 5 139,164,926.75 182,743,467.90 158,084,663.61 22,164,157.62 
Further in Table 4.2.2 and figure 4.2.1a summary was prepared to show the percentage 
cost per annum to total medical cost incurred in the in-house medical scheme. There 
has been consistent upward trend among all the cost drivers of the in-house medical 
scheme. The analysis revealed that administrative costs contributed to 15% of the total 
cost in 2011 which declined to 13.2% in 2013 and increased to 14.6% in 2015. The 
doctors’ consultation contributed to 29% of the medical cost in 2013 and had the 
highest contribution in 2015 which clearly stipulated that there were many referral 
cases of employees as well as their dependants. The mean pharmaceutical costs was at 
10.3% in 2011 and declined to a low contribution of 5.8% in 2012 after which it 
reversed the trend and increased up to 11.5% in 2015.  
Table 4.2.2 Expenditures as Percentage of Medical Scheme Expenditure 
Year 2011 2012 2013 2014 2015 
Pharmaceutical costs  10.3 5.8 6.6 7.3 11.5 
Medical Technology 
expenditure  4.4 1.1 2.2 1.6 3.3 
Chronic illness 17.7 14.5 9.9 10.8 10.1 
Length of stay (Expenditure in 
Kshs.) 11.6 21.7 22.9 25.6 19.9 
Long term care expenditure 0.0 0.0 0.0 0.0 0.0 
Doctors consultation 2.0 17.7 28.5 27.0 29.6 
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Administrative Expenditure 15.3 14.6 13.2 14.2 14.6 
 
 
Figure 4.2.1 Trend Analysis on Percentage of Component Cost 
Pharmaceutical expenditure 
Further, the study examined the trend analysis of the pharmaceutical cost from 2011 
to 2015, although there was a downward trend from Kshs. 28.3 million in 2011 to 
Kshs. 19.3 million in 2012, an upward trend was recorded from 2012 to 2013 with 
Kshs. 27 million, the cost escalated consistently to Kshs. 60 million in 2015 as 
demonstrated in figure 4.2.2 below. In relation to the pharmaceutical expenditure as 
percentage of the total scheme expenditure, it was 10.3%, 5.8%, 6.6%, 7.7%, and 
11.5% in 2011, 2012, 2013, 2014 and 2015 respectively as shown in fig 4.2.1 above. 
In this period pharmaceutical expenditure never took lead as the highest expenditure. 
Nevertheless there is need for cost minimization strategy to be developed more so on 





Figure 4.2.2 Pharmaceutical Cost 
Demographics Shift 
Demographic shift was examined in age, gender and growth over the study period. 
Figure 4.2.3 indicates that majority (53%) of the in house medical scheme beneficiaries 
were female and male accounted for 47%. Further, table 4.2.3 shows the distribution 
of gender changes within the period under investigation, in the year 2012 the increase 
of medical cover beneficiaries was the same at 50%, in 2013 more female’s (52.3%) 
benefited as compared to male though the pattern was revised in 2014 and 2015 where 
male increased to 51.7% and 50.9% respectively. 
 
 
Figure 4.2.3 Gender 
32 
 
Table 4.2.3 Gender Shift 
Year Gender Frequency Percent 
2011 Male 2515 46.1 
 
Female 2944 53.9 
 
Total 5459 100 
2012 Male 99 50 
 
Female 99 50 
 
Total 198 100 
2013 Male 123 47.7 
 
Female 135 52.3 
 
Total 258 100 
2014 Male 136 51.7 
 
Female 127 48.3 
 
Total 263 100 
2015 Male 173 50.9 
 
Female 167 49.1 
 
Total 340 100 
Age distribution as demonstrated in table 4.2.4, majority 14.3% of the beneficiaries 
scheme was aged between 0-4 years, followed by 11.9% who aged between 11-14 
years, 10.6% aged between 15-20 years and 10.1% aged between 5-9 years. There is 
need for the provision of affordable pediatrician medical services so as to optimize 
utilization of the available medical services as provided by the in-house medical 
scheme. 
Table 4.2.4 Age Distribution 
Age Groups Frequency Percent 
0-4 930 14.3 
5-9 658 10.1 
11-14 777 11.9 
15-20 690 10.6 
20-24 595 9.1 
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25-29 311 4.8 
30-34 402 6.2 
35-39 514 7.9 
40-44 540 8.3 
45-49 478 7.3 
50-54 438 6.7 
55-59 147 2.3 
Above 60 38 0.6 
Total 6518 100 
 
A close scrutiny of beneficiary’s trend analysis table 4.2.5, revealed that those aged 
between 0 to 4 years were the greatest beneficiaries across the five year period under 
investigation, which implies that most of the employees have many young children 
who could be in constant need of medical attention.  
 
Table 4.2.5 Age Distribution in the Five Years 
  2011 2012 2013 2014 2015 
  F % F % F % F % F % 
0-4 522 9.6 94 47.5 97 37.6 105 39.9 112 32.9 
5-9 549 10.1 21 10.6 21 8.1 18 6.8 49 14.4 
11-14 725 13.3     22 8.5 12 4.6 18 5.3 
15-20 667 12.2     6 2.3 7 2.7 10 2.9 
20-24 560 10.3     8 3.1 18 6.8 9 2.6 
25-29 159 2.9 35 17.7 28 10.9 38 14.4 51 15 
30-34 273 5 26 13.1 40 15.5 30 11.4 33 9.7 
35-39 424 7.8 12 6.1 20 7.8 20 7.6 38 11.2 
40-44 504 9.2 4 2 9 3.5 12 4.6 11 3.2 
45-49 466 8.5 3 1.5 4 1.6 1 0.4 4 1.2 
50-54 430 7.9 2 1 2 0.8 1 0.4 3 0.9 
55-59 144 2.6 1 0.5 1 0.4     1 0.3 
Above 60 36 0.7         1 0.4 1 0.3 
Total 5459 100 198 100 258 100 263 100 340 100 




Further, the study used population pyramid to examine the population distribution 
within the five year period as summarized in Figure 4.2.4. Although, male population 
was high in 2011, female beneficiaries grew at a faster rate compared to male and the 





Medical Technology Expenditure 
Although, there are different technologies which have been adopted in the provision 
of quality medical care, the current study examined annual costs incurred on CT 
(Computed Tomography) Scan, U/S (Ultra Sound), Magnetic Resonance Imaging 
(MRI), endoscopy/colonoscopy and x-ray that were found to be commonly used 
technologies in the study case Table 4.2.2 above, demonstrates that medical 
technology as a percentage of Medical Scheme expenditure varied over time. In 2011 
it was at 4.4% of the total medical scheme expenditure the highest in the study period, 
Figure 4.2.4 Pyramid of Age Distribution 
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declining to the lowest in 2012 at 1.1%. In 2013 it was 2.2%, 1.6% and 3.3% in 2014 
and 2015 respectively. Results of the study were tabulated as shown in Table 4.2.6 
using range, mean and standard deviation. The mean cost incurred on CT scan was 
Kshs. 1.2 million with a minimum of Kshs. 0.6 million and a maximum of Kshs. 2.9 
million. This implies though in some period the CT scan cost was high, in some periods 
it was not preferred. Secondly, although U/S had a mean of Kshs. 1.4 million, its cost 
across the period reduced since it had a mean deviation of Kshs. 0.9 million as 
compared to CT scan with a mean deviation of Kshs. 1  million.  Thirdly, MRI had a 
mean of Kshs. 1.3 million. Concerning adoption of endoscopy/colonoscopy the mean 
cost was Kshs. 0.9 million, moreover, it recorded the minimum cost of Kshs. 106, 000. 
Finally, X-ray charges had a mean cost of Kshs. 5.1 million which indicates it was the 
most preferred medical technology by the medical providers; this could be attributed 
to its cost and the indications of X-rays compared to the use of other alternatives.  
Table 4.2.6 Medical Technology Expenditure 
 
N Minimum Maximum Mean 
Std. 
Deviation 
CT scan 5 
       
526,965.00  
   
2,987,562.0
0  
   
1,207,024.4
0  
   
1,020,755.77  
U/S 5 
       
596,200.00  
   
3,022,588.0
0  
   
1,421,991.2
0  
       
937,510.99  
MRI 5 
       
209,000.00  
   
3,360,682.0
0  
   
1,333,320.4
0  




       
106,000.00  
   
2,890,035.0
0  
       
889,010.60  
   
1,151,350.33  
x-ray 5 
   
1,460,794.50  
   
8,927,081.6
0  
   
5,111,321.4
7  





Further, the study sought to examine the percentage contribution of CT scan, U/S, 
MRI, Endoscopy/colonoscopy and X-rays to the overall medical technology cost from 
2011 to 2015 as shown in figure 4.2.5 below. In all the years, X-rays contributed the 
highest percentage. In 2011 it had 73.5% as compared to endoscopy/colonoscopy 
showing dominance of X-ray technology, through to 2015.Diversified medical 
technological approaches have been adopted by health practitioners as they endeavor 
to provide quality medical care. Although, U/S had increased to 35.9% in 2012 it 
recorded a huge decline in 2013 to 10.9% but the trend reversed in 2014 and 2015 with 
an increase to 15.4% and 17.3% respectively. There is need for evaluation of the 
triggers of downward trends in medical technology in 2012 to 2013 though reversal 
trends were recorded in 2013 to 2015 with only X-rays declining to 29.7% in 2015 
with an initial percentage of 73.5% in 2011.  
 
 






An examination of cost charges incurred on chronic diseases was summarized in Table 
4.2.7 using descriptive statistics. The mean annual medical charges on heart and blood 
conditions was Kshs. 10.8 million with a minimum of Kshs. 7.8 million and a 
maximum of Kshs. 15.8 million. Diabetes mean costs was Kshs. 6.8 million. There is 
cause for alarm on the high annual costs associated with musculoskeletal conditions 
which had a mean of Kshs. 21.9 million with a minimum of Kshs. 14.9 million and a 
maximum of Kshs. 33.7 million. Although, mental illness recorded the least mean 
among the chronic condition, annual cost with a minimum of Kshs. 1 million and 
maximum of Kshs. 5.4 million calls for evaluation of strategies to minimize 
possibilities of contracting mental illness and seeks measures to control those who are 
already suffering from it. Finally, the mean cost incurred on cancer treatment had the 
elephant share on chronic illness cost with a mean of Kshs. 6.1 million and maximum 
of Kshs. 33.4 million which call for measures to mitigate this cost which can have 
constraining effect on medical expenses.  
 
Table 4.2.7 Chronic Diseases in Kshs 
 
N Minimum Maximum Mean 
Std. 
Deviation 
Heart & blood 
conditions 5     7,817,556    15,760,258 
   
10,776,016      3,239,593 
Diabetics 5 
     
3,646,299    12,002,440 
     
6,827,325      3,378,777 
Musculoskeletal  
conditions 5 
   
14,887,052    33,662,546 
   
21,863,085      7,052,294 
Mental illness 5 
     
1,030,507      5,349,848 
     
2,665,193      1,863,149 
Cancers 5 
     
6,036,082    33,337,674 
   
16,917,509    10,168,310 
 
In aggregate chronic conditions as a percentage of the total medical scheme 
expenditure was highest in 2011 at 17.7% and lowest at 9.9% in 2013. While in 2012 
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it was 14.5%, 10.8% in 2014 and 10.1% in 2015 Table 4.2.2 above. These findings 
suggest some decline trend over time though not sustained. 
The pictorial presentation in Figure 4.2.6 the percentage of the chronic disease cost to 
the overall medical cost, both cancer and musculoskeletal conditions need to be 
examined carefully since they contributed the highest percentage of the total cost. 
Measures taken to curb the spread of diabetes ought to be intensified as such to 




Figure 4.2.6 Percentage of Chronic Disease Cost to Total Chronic Diseases 
Expenses 
 
Length of hospital stay 
Although, the length of stay in a health facility as summarized in figure 4.2.7 has 
recorded a downward trend from 8.8 days in 2011 to 5.0 days in 2015, there was a 
reversal in 2013 since the days increased from 4.4 to 6.5 days in 2012. The current 
status should be managed so as to minimize cost since throughout the period the 
number of days are lower compared to global statistics from Japan and Germany where 




Figure 4.2.7 Length of Hospital Stay in Days 
The expenditure for hospital stay was calculated as total direct cost. Figure 4.2.8 shows 
the upward trend in hospital admission. In 2011 the expenditure was Kshs 42 million 
and 48 million, 54million, 64million and 76million in 2012, 2013, 2014 and 2015 
respectively. This translates to 11.6%, 21.7%, 22.9%, 25.6% and 19.9% of the total 
medical scheme expenditure as demonstrated in Table 4.1 above. Cost due to the 
length of hospital stay is a significant cost driver in this medical scheme. 
 
Figure 4.2.8 Length of Stay Expenditure 
Administrative expenditure 
The pictorial presentation in Figure 4.2.9shows, there was a consistent upward trend 
on annual medical administrative cost. A thorough administrative cost evaluation 
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ought to be carried since there is a mean monthly cost increment of at least Kshs. 10 
million. Further, as time elapses administrative cost increases at a faster rate compared 
to initial periods. Administrative cost as a percentage of the total medical scheme 
expenditure was found to be of significance as shown in Table 4.2.2above. It was 




Figure 4.2.9 Trend Analysis of Administrative Cost 
 
Doctor’s Consultation Fees 
Doctors’ consultation was the highest in expenditure all through the 2011 to 2015 as 
demonstrated in figure 4.2.1 above. In 2011, 2012, 2013, 2014 and 2015 it was 2%, 
17.7%, 28.5%, 27.0% and 29.6% respectively. A whopping 49.64% increase in 2013 
recording from Kshs 58,679,485 in 2012 to Kshs 116,531,261.40 in 2013 as shown in 




Figure 4.2.10 Trend Analysis on Doctor's Consultation Fees 
 
4.3 Qualitative Analysis of Cost Containment Strategies 
The Medical Scheme policy document and its operations manual were reviewed.  
During 2011 to 2015 the July 1996 edition was in use and was later reviewed in 
November 2014. The medical scheme operation manual hereby referred to as an 
operations manual was revised after the installation of the EMR in 2010. The following 
findings on medical scheme and cost control policy were extracted from these 
documents. 
Pharmaceutical measures 
The medical scheme allows use of both branded and high quality generic drugs, 
dressings and other medical or surgical materials purchased on recommendation 
through the procurement policy. Branded drugs are expensive and contribute to high 
costs compared to high quality generic drugs which are cheaper. The policy is not clear 
on what extend of use of branded drugs in terms of drug tiers. Neither are there 
healthcare provider incentives on more use of generic drugs in order to contain cost. 
A list of drugs is prepared by the pharmacist from the previous financial usage. This 
is then presented to committee to formulate the formulary. The drug formulary with 
specifications is issued to the procurement office. A drug formulary is a cost 




Before dispensing, the pharmacist counterchecks the prescription in terms of dosage 
and duration. However the scheme lacks prescription audit which should be 
periodically carried out to avoid overuse. Besides that, the scheme lacks control 
measures on number of drugs per prescription and particularly on non-chronic 
conditions. Antibiotics add to the high costs due to misuse when not regulated. The 
Medical Scheme needs to develop a policy on antibiotic use, as a cost measure and 
secondly, to avoid resistance to antibiotic treatment brought on by misuse. 
The policy does not state on claims arising from self-referral prescriptions or drugs 
dispensed over the counter. It does not limit on drug costs or number of day’s supply 
of drugs to be dispensed. Claims on drugs from external hospital outside Clinic hours 
are honored and reimbursed. 
The documents do not state on patient request on drugs without a prescription. This 
can be a cause of high drug expenditure. The documents do not also define expiry of 
allowed number of days a single prescription can be dispensed especially for chronic 
conditions. This is a cost measure which minimizes wastage. 
Loss of drugs or breakage of bottles containing newly dispensed drugs is not addressed 
in either document on how the matter should be handled. This would ensure 
accountability. Cost sharing on replacement would be cost containment. 
Administrative gate keeping 
A number of administrative gate keeping measures are taken. Claims are only paid 
after an audit process that scrutinizes the invoices to ensure that prescriptions are from 
approved medical service providers, and have the correct amount, date of referral, staff 
number and name of patient. Secondly, the scheme can only honor a claim that had a 
pre-hospital authorization, and where the services rendered were in line with the 
benefits and entitlements that are outlined in the policy. Thirdly, the scheme only pays 
after in-patient NHIF rebate. Lastly, the scheme only offers medical services in the 
areas indicated in the schedule and exclusions as listed in the schedule. Admission to 
private ward must be justified by the admitting institution because the scheme caters 
for beds in the general ward. An eligible employee who does not contribute to the 
National Hospital Insurance Fund or an eligible member of his family may only be 
admitted, at the organization’s expense to a general ward of a government. The 
Scheme in these cases, meets the admission fees and other charges incurred on 
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production of receipts. If the employee referred above, is admitted to a private ward, 
he will be required to pay the difference between the charges in the general ward. 
The scheme maintains a list of approved medical service providers. The terms and 
conditions with the contracted health service providers are not provided in these 
documents. On admission the letter for undertaking states the amount that should not 
be exceeded and items that the scheme does not pay. For individual service provider, 
the scheme enters into a negotiated consultation fee and also informed of limitation of 
services. On Beneficiary legitimacy, frequency and contribution the scheme has a 
synchronized system. The members of the staff medical scheme have the facility 
extended to their spouse (1) and children below twenty five years (25) of age. Staff 
members are allowed free cover fora maximum of four children below 18 years of age. 
The scheme allows additional children above the four and over 18 years on a token 
contribution of Kshs.500 per month per child. Refunds will only be considered for 
services received from any medical facility when the scheme clinic is closed and the 
condition is considered an emergency. 
Other administrative measures to control and monitor cost is by sending summary of 
the invoices amounting to Kshs. 100,000 and above to one beneficiary is prepared and 
approved. The summary is manually sent for approval and authorization to the 
Director, of Finance. The budget is monitored on a continuous basis with variance 
analysis carried out on monthly basis. 
Budget variance reports are accessed on line from the Hyperion system, and a printout 
is obtained for analysis on monthly basis. Variances both positive and negative from 
5% are analyzed and accounted for. 
Risk sharing and low cost options are not discussed. Other omissions include, terms 
and condition of services on fee arrangements with Hospitals and doctors’ 
consultation. 
 
Need & demand reduction 
There are programs in place to improve fitness they include; wellness programs and 
health education (talks, seminars etc.) as Preventive Health services. Limitation of two 
caesarean section is allowed to both staff and spouses of staff. No information on 
incentives for the beneficiaries for cutting health care cost was found. 
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Incentive to health care providers and beneficiaries 
Guidelines for management of certain conditions would not only control cost but also 
motivate the health workers as a result of improved cure rate and better outcome. No 
information regarding appraisal of the doctors’ performance in terms of number of 
drugs per prescriptions or number of referrals. While consultations and drugs are cost 
drivers in medical scheme health care, workers should be motivated to cut cost. 
Patient coordination care 
Discussions with the referral doctors on patients with complex or chronic conditions 
have been encouraged in these documents. There is however, no policy on disease 
management programs, which empowers the patient to learn about their condition and 
how to manage themselves around the chronic conditions. There is no policy on 
terminally ill patient on length of care besides the stated services. Seeking for second 






CHAPTER FIVE: DISCUSSION, CONCLUSION AND 
RECOMMENDATIONS 
5.1 Introduction 
In this section the study presents the discussion, conclusion and recommendations. In 
this chapter all sections are arranged according to the study objectives.  
5.2 Discussion of Findings 
The current study sought to examine the cost drivers of health care for in-house staff 
medical scheme of an organization. The study adopted descriptive designs and 
secondary data was collected from in-house medical records. Descriptive analysis 
using mean, standard deviation, range, frequency and percentage were used to analyse 
the data. It was found that, most of the beneficiaries were females who aged between 
0-4 years and most of the female employees had low attrition rates from the 
organization employment as compared to males. All medical costs registered an 
upward trend throughout the period under investigation. There is cause for alarm since 
most of the beneficiaries are suffering from chronic illness which calls for continued 
attention which may strain in-house medical budget.  
A spot check on all cost drivers considered in the study revealed that pharmaceutical 
cost was second to chronic illness costs. This contrasted OECD (2015) which found 
that pharmaceutical expenditure is the key driver of medical cost which takes almost 
20% of the total medical health care cost of a given country.   
Although medical technology cost had a minimum of almost Kshs. 4 million, with 
maximum cost of Kshs. 17 million, there were chances of overusing technology driven 
treatment approaches or the medical scheme beneficiaries have switched to it as they 
seek to treat untreatable conditions by substituting traditional methods. Moreover, 
discovery of new diagnosing approaches may have been adopted by different medical 
providers serving the organization in-house Medical Scheme beneficiaries Goyen & 
Debatin, (2009). Although, a heathy working population may trigger motivation in the 
work force, there is need to monitor medical costs and advocate the use of technology 
driven treatment when the condition deserves so.  
Even if the chronic diseases costs had the highest average it did not record the highest 
costs all the years as compared to pharmaceutical costs. Since this cost was mostly 
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incurred through consultants there is need to organize in-house training sessions on 
lifestyle diseases which include diabetes and cancers, among others. The organization 
should sensitize its workforce on how to mitigate these diseases which seem to be on 
the rise among the workforce and their beneficiaries. These results seems to mirror 
Bodenheimer et al., (2009) who argued that in America the recorded cases of chronic 
illness seem to be on upward trajectory and there are high chances of them increasing 
cost burden to almost 80% of health spending by the year 2020.  
 Although, the average annual hospitalization cost averaged at Kshs. 83.4 million, 
annual cost charges differed so much which indicated possibilities of some period 
recording least hospitalization cost as compared to others. From the global and 
regional statistics on length of stay, the average period is in agreement with OECD 
(2017c) which has recorded lengths of stay ranging from 5.1 days to 16.9 days. 
Although, there is no documented evidence on uncoordinated care in this medical 
scheme there is need to regulate the period and consequently minimize medical 
expenditure associated with length of stay. This can be achieved through a coordinated 
pool of experts from different sectors who develop cost minimization strategies.  
Although, there was recorded evidence on provision of long term care it was offered 
only in one year. To the employees, provision and subsequent withdrawal of this 
service after one year is not clear because in the policy review there was no 
documentation that would explain this: yet long term care can be used to minimize 
hospital admission and encourage homecare.  In contrast, the management may 
perceive low uptake of this service as indication of low social support whereby patients 
don’t prefer to be at the comfort of their home and loved ones as opposed to being in 
hospital. 
Demographic shift data trend conflicted the global trends on population growth rate 
which are currently projected to be 9% though expected to grow asymptotically to 20% 
by the year 2050 (Beard et al., 2012). Through this growth, the expectations on the 
demand of health care services will ultimately increase health care costs in the in-house 
medical scheme.  
 
The management will be able to monitor patient coordinated care as a cost containment 
measure and manage medical cost inflation since Folland et al., (2007) argued that 
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there are possibilities of escalating medical charges owing to more consultation, test 
and over drug prescription. Owing to these charges there is need to evaluate 
independent costs drivers and devise mechanisms aimed at minimizing medical costs 
without compromising quality care and altering employees’ motivation upon 
triggering fringe benefits associated with provision of medical cover. 
The scheme policy and guidelines on medical cost containment were explored with a 
check list developed from the literature review on pharmaceutical cost containment 
measures. The procurement process is a key measure that has helped the scheme save 
on drug expenditure because of drug formulary use. Competitive price of drugs is 
encouraged by the public open tender that the scheme applies to acquire suppliers of 
the drugs. Though this poses the risk of low quality, it is a cost saving measure and 
spreads risk among different suppliers as opposed to having single source. However; 
there are gaps on utilization of drugs. The scheme should limit number of days’ routine 
drug are dispensed on discharge from the hospital and limitation of claims; for 
example, indicate number of claims a staff can make per month. Due to the lack of 
these limitations, there have been cases of double purchases of same drugs. Other 
measures that were not stated in these document were measures on drug utility, terms 
and condition of drug reimbursement and periods to expiration of prescriptions from 
external doctors. Luck of filling these gaps in the two documents has contributed to 
minimal control on drug usage. 
Administration gate keeping is well defined compared to the other containment 
measures discussed in this study. Auditing of membership legitimacy has been 
discussed and therefore adhered to as demonstrated from the demographic shift. Exit 
from the scheme was either through attaining retirement age, overgrowing the scheme 
by turning 25years, job termination, or death. Contribution from the 18th birthday is 
prompt. The scheme allowing a limited number of children covered by the scheme is 
cost containment measure which has encouraged copayment as a token. Though Kshs. 
500 is very minimal considering the price inflation, it is a source of funding for the 
scheme. The scheme has a referral system in place; however, doctor’s consultation 
expenditure has been noted to rise over the study period. More study needs to been 
done to establish which specialty is the scheme spending more on and strategies 
developed towards containing these costs. For instant, hiring visiting consultants to the 
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clinic and contract them on hours worked can be encouraged as opposed to service for 
fee. 
Another measure that has worked for this scheme is the pre- hospital authorization. 
This has controlled the self-referral cases apart from instances of emergencies. Under 
administration gate keeping a gap was found, the documents did not state the risk 
sharing and low cost option. Charge arrangement with hospital for inpatient is not 
documented. There is no system in place that encourages admitting hospitals to 
communicate to the scheme about new admission cases. This is important because in 
case of emergency admission, the scheme staff can do a follow up and observe 
coordinated care for the patient. This eliminates unnecessary tests and treatment. The 
documents do not state who’s to make hospital visits to monitor care and cost. In 
researcher’s view the medical doctor would be in better position to monitor each 
patient’s treatment from the principle doctor. The terms of contract for external health 
care providers is not stated. For instance number of review visits posts e.g. caesarian 
section or surgery the documents lack this control of visits. In addition the documents 
do not state the expiry of a single referral letter in case a patient is sent for laboratory 
tests or radiography by the doctor referred to. It should be clear whether a patient 
should present a fresh referral if within e.g. 48hours or 72hours.  
Need and demand control has programs in place to ensure for example physical fitness. 
Though no evidence, the organization policy on health programs like gym and sports 
have gone a long way in reducing cases of chronic conditions. The scheme documents 
do not give any information on how the scheme beneficiaries can be involved to make 
decisions on how to contain cost. It would be commendable to have a suggestion box 
or a portal that the beneficiaries can use to air their views. The beneficiaries can 
introduce ideas that can benefit the scheme and the management can involve the 
beneficiary in times when they are making decisions that directly affect them. 
From the documents, appraisal of the health care providers in regard to cost 
containment is not discussed. Though this requires care, to ensure that quality of 
patient care is not compromised. 
The scheme documents have no documentation on patient care guidelines, disease 
management programs, terminally ill patient care or use of second opinion before 
arriving to a concluded treatment. Guidelines and management programs would 
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address the cost escalation on chronic conditions. This ensures safety and quality of 
drugs supplied.  
5.3 Conclusion 
The cost drivers in this scheme reflected differently from what gathered from the 
literature review. Traditionally an aging population has been associated with high 
health care cost. For this study above 60years where very few yet chronic diseases 
expenditure was significant even higher than pharmaceutical expenditure. The 
numbers of beneficiaries steadily grew at a rate of 6% and therefore a justification for 
increase in health care expenditure. The growth in the expenditure was not 
proportional to the population growth, more so in 2013. Population is composed of 
more between o to 4 years and 11to 14 years with very few above 60 years. The chronic 
diseases are therefore not as a result of old age. This findings agreed with (Barros, 
2010), that aging population had no significant to health expenditure. 
 Doctors’ consultation was the highest all through the study period, indicating many 
referrals to the external doctors. Pharmaceutical expenditure was contrary from 
literature review of 20% of the total scheme expenditure. Length of hospital was way 
below majority of countries but the hospital admission cost was significant to the 
scheme. There was high cost in musculoskeletal conditions which needs to be 
investigated further since the organization does not directly prone to physical injuries. 
The musculosketal injuries explain the high cost of x-ray in the scheme. 
The employer has a pivotal role on managing cost; several cost drivers considered in 
the study have registered an upward trend which is cause for alarm since in some 
instances the costs have increased very fast.  
Though (Barros, 2010), did not find the role of gatekeeping and institutional features 
significant in containing cost, the findings in this study case differed. Policies have a 
big role in cost containment because they dictate utilization of the scheme as while as 
use of guidelines .This scheme lacks water tight policies that control wastage and 
incentive to the health workers who are key gatekeepers in health and the scheme 
beneficiaries. The increase in doctors’ consultation would be associated with 




Medical scheme is a powerful tool for staff welfare. Policies that minimize misuse and 
waste without compromising quality of care are a great foundation for a sustainable 
scheme. 
5.4 Recommendations 
Following the identifying the key cost drivers of the study case, there is need for policy 
reforms for the medical scheme. Policies need be reviewed and implemented after 
three years. This is because the medical field is dynamic and hence the need to keep 
with policies that keep the scheme guarded and guided. For instant more policies on 
drug utilization is key considering that it has been a significant cost driver in this 
medical scheme and involve all stakeholders of the scheme when reviewing the 
policies. This can be done by beneficiary representatives. 
Administrative keeping on developing measures to minimize medical cost from 
different cost drivers. For instance; pharmaceutical products can be accessed on 
wholesale rather than retail method, execution of horizontal alliances with other 
government parastatals and ministries, lifestyle seminars, workshop and short courses 
should be held continuously as such to manage the spread of lifestyle related diseases 
especially diabetes which seems to be on upward trends. Encourage the organization 
to continue hiring employees of below 40years because majority are not associated 
with chronic conditions. 
Preventive health care, provision of both sporting and psychological amenities 
amongst employees at no cost and all employees should be encouraged to participate.  
Copayment to the scheme by the beneficiaries has proven to be incentive to cost 
control, because it changes the behavior in utilization. The management can involve 
the stakeholders concerning copayment or capitation in order to sustain the scheme in 
future. 
Encourage spouses to disclose other medical scheme. Hospital admissions should be 
monitored closely because they are contributing to high percentage of expenditure. 
The scheme needs considers having number of days expected for each medical 
condition so closer monitoring of hospital stay. Utilization of committees which can 
oversee different utilities, for example there can be committee for referrals, 
admissions, drugs etc. to monitor expenditures. 
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5.5 Suggestions for Further Studies 
Although, the current study adopted use of secondary data, future research should 
adopt the use of primary data as such to examine the qualitative cost drivers of medical 
cost amongst beneficiaries of in house medical scheme. From this study it will be 
appropriate to retrieve the first hand information from beneficiaries on their perception 
on costs drivers and the respective cost containment measures to be taken.  
Secondly, though the study adopted the use of annual secondary data, future study 
should examine the causal effect between medical cost and cost drivers using monthly 
or daily data so as to examine both short and long run relationship between the 
respective cost drivers. Moreover, through this approach, in-house medical providers 
would be in a position to examine regular trends and seasonal approach solutions 
would be developed.   
Interestingly, the management has to consider motivational roles on their employees 
as they provide medical cover and minimize annual medical costs incurred. There is 
need to examine the effect of provision of medical cover, its influence to employees 
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Appendix I Research Data Collection Instrument 
Population Growth    
Year Staff dependents Total 
2011    
2012    
2013    
2014    
2015    
 
Population in age range in years 
Age Range 2011 2012 2013 2014 2015 
0-4      
5-9      
10-14      
15-19      
20-24      
25-29      
30-34      
35-39      
40-44      
45-49      
50-54      
55-60      








Appendix C: Length of hospital stay  
 
Year 2011 2012 2013 2014 2015 
LOS           
Expenditure           
 
Physician’s visits and consultations (referrals) 
 
Year 2011 2012 2013 2014 2015 
Expenditure      
 






2012 2013 2014 2015 
CT scan      
MRI      




     
PET scan      
TOTAL      
 
Pharmaceutical Expenditure 
Year 2011 2012 2013 2014 2015 
Internal Drug 
expenditure 
     
External drug 
expenditure 
     






Chronic diseases expenditure 
 2011 2012 2013 2014 2015 
Heart & blood 
diseases 
     
diabetics      
musculoskeletal 
disorders 
     
Mental 
disorders 
     
cancers      
Total      
 
Administrative cost   
This is inclusive of salaries & wages, Pensions Fund, pensions Fund contribution, 
gratuities for contract staff, duty and special allowance, NSSF contributions, tax-top 
allowances, leave allowance, fringe tax and AC and DC contributions 
Year 2011 2012 2013 2014 2015 
Expenditure      
 
Long term care 
Number of cases admitted in different facilities for more than 100 days in single 
admission either as Hospital admission, Home care with nurse aid, Rehabilitation 
Centre or Mental Hospital. 
 
Year 2011 2012 2013 2014 2015 











Appendix II Document Review for cost Containment Measurement tools 
Pharmaceutical measures   
·         Procurement of drugs   
·         Formulary (use of generic  versus branded drugs)   
·         Reimbursement of drugs   
·         Medicine utilization   
Administration Gate keeping   
·         Auditing beneficiary legitimacy &frequency   
·         Referrals   
·         audit of claims   
·         Pre-hospital authorization   
·         risk-sharing and low cost-options   
·         charge arrangements to the hospitals   
·         contract  terms and conditions with providers   
·         contract  terms and conditions with hospitals   
·         beneficiary contribution   
Need & demand reduction   
·         Health programs in place for the scheme beneficiaries   
·         beneficiary involvement in decision making   
Incentive to health care providers & patients   
·         performance appraisal on cost containment   
Patient coordination care   
·         patient care guidelines   
·         disease management programs   
·         terminally ill patient care   
·         take on second opinion   
 
